Alogliptin in a batch of Japanese launches for Takeda
This article was originally published in Scrip
Executive Summary
Takeda has launched its DPP-4 inhibitor antidiabetic, alogliptin, in Japan, as Nesina, for the treatment of type 2 disease inadequately controlled by diet and exercise or this regimen plus alpha-glucosidase therapy.